Cypherpunk Technologies Inc (CYPH) Stock Price, Quote & News

Company Profile

Cypherpunk Technologies Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-501, a monoclonal antibody that inhibits GDF-15 protein that is in preclinical trial. It has an optio...

Industry: Asset Management

Sector: Financial Services

Phone: 617 714 0360

Website: www.leaptx.com

Address:

47 Thorndike Street, Suite B1-1, Cambridge, United States

atechniqueisause Mar. 14 at 12:34 AM

$CYPH So, earnings report on Tuesday? We expecting something?

1 · Reply

DubLad76 Mar. 13 at 8:38 PM

$CYPH how does this price make any sense?

0 · Reply

atechniqueisause Mar. 13 at 1:44 PM

$CYPH Let's go bros!

0 · Reply

BiodegradableBurger Mar. 13 at 8:46 AM

$CYPH Looking forward to the next pump.

0 · Reply

wutzwrong Mar. 13 at 3:58 AM

$CYPH earnings 3/17

0 · Reply

DubLad76 Mar. 12 at 5:08 PM

$CYPH keep on buying till I average down to 0.50 Then, well, wait for the big bounce.

0 · Reply

StockDreamin Mar. 12 at 2:12 PM

$CYPH antique sauce is on a roll! Yeah buddy!

1 · Reply

atechniqueisause Mar. 12 at 1:28 PM

$CYPH Cypherhunks?, Cypherchumps?, Cypherflunks?

0 · Reply

DubLad76 Mar. 11 at 9:06 PM

$CYPH

1 · Reply

Insideroutcalls Mar. 11 at 3:53 PM

$CYPH

0 · Reply

Cypherpunk Makes $5M Investment into Zcash Open Development Lab (ZODL)

Jan 22, 2026, 7:00 AM EST - 7 weeks ago

Cypherpunk Adds Arjun Khemani as Strategic Advisor

Dec 30, 2025, 7:00 AM EST - 2 months ago

Cypherpunk Accelerates Zcash Accumulation; Increases Treasury Holdings to 290,062.67 ZEC

Dec 19, 2025, 7:00 AM EST - 3 months ago

Josh Swihart, ECC CEO, Joins Cypherpunk as Strategic Advisor

Dec 15, 2025, 12:59 PM EST - 3 months ago

Cypherpunk Technologies Inc. (CYPH) Leap Therapeutics, Inc. - Shareholder/Analyst Call Prepared Remarks Transcript

Dec 9, 2025, 7:00 AM EST - 3 months ago

Cypherpunk Taps Zcash Founder Zooko as Strategic Advisor

Nov 12, 2025, 8:00 AM EST - 4 months ago

Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results

Nov 12, 2025, 7:00 AM EST - 4 months ago

Leap Therapeutics Rebrands as Cypherpunk; Expands Leadership Team to Drive New Zcash Treasury Strategy

Oct 20, 2025, 7:00 AM EDT - 5 months ago

Leap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025

Oct 9, 2025, 7:00 AM EDT - 5 months ago

Leap Therapeutics Announces Closing of $58.88 Million Private Placement in Cash Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy

Oct 6, 2025, 9:00 AM EDT - 5 months ago

Leap Therapeutics Announces $58.88 Million Private Placement in Cash Commitments Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy

Sep 25, 2025, 7:00 AM EDT - 6 months ago

Leap Therapeutics to Present Final Clinical Data from Part B of the DeFianCe Study at the ESMO Congress 2025

Aug 14, 2025, 7:00 AM EDT - 7 months ago

Leap Therapeutics Reports Second Quarter 2025 Financial Results

Jun 23, 2025, 7:00 AM EDT - 9 months ago

Leap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic Alternatives

May 13, 2025, 7:00 AM EDT - 10 months ago

Leap Therapeutics Reports First Quarter 2025 Financial Results

Apr 25, 2025, 1:00 PM EDT - 11 months ago

Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual Meeting

Apr 15, 2025, 7:00 AM EDT - 11 months ago

Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer

Mar 31, 2025, 1:42 PM EDT - 1 year ago

Leap Therapeutics (LPTX) Conference Call to discuss Updated Data from Part B of the DeFianCe Study Transcript

Mar 26, 2025, 1:29 PM EDT - 1 year ago

Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer

Mar 26, 2025, 7:05 AM EDT - 1 year ago

Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 26, 2025, 7:00 AM EDT - 1 year ago

Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study

Jan 28, 2025, 7:00 AM EST - 1 year ago

Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study

Jan 6, 2025, 7:01 AM EST - 1 year ago

Leap Therapeutics: A Buy On Near-Term Data Catalysts In Stomach And Colon Cancer

Jan 6, 2025, 7:00 AM EST - 1 year ago

Leap Therapeutics to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 26, 2024, 7:00 AM EST - 1 year ago

Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference

Nov 13, 2024, 7:00 AM EST - 1 year ago

Leap Therapeutics Reports Third Quarter 2024 Financial Results

Sep 30, 2024, 7:00 AM EDT - 1 year ago

Leap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

Aug 12, 2024, 7:00 AM EDT - 1 year ago

Leap Therapeutics Reports Second Quarter 2024 Financial Results

May 13, 2024, 7:00 AM EDT - 1 year ago

Leap Therapeutics Reports First Quarter 2024 Financial Results

Apr 11, 2024, 8:30 AM EDT - 2 years ago

Leap Therapeutics Announces $40 Million Private Placement

Mar 18, 2024, 7:00 AM EDT - 2 years ago

Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Jan 16, 2024, 5:05 PM EST - 2 years ago

Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium

Jan 3, 2024, 7:00 AM EST - 2 years ago

Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 2, 2024, 7:00 AM EST - 2 years ago

Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients

Dec 11, 2023, 4:05 PM EST - 2 years ago

Leap Therapeutics to Present New Data from Part A of the DeFianCe Study of DKN-01 Plus Bevacizumab and Chemotherapy in Colorectal Cancer Patients at the 2024 ASCO Gastrointestinal Cancers Symposium

Nov 21, 2023, 7:00 AM EST - 2 years ago

Leap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare Conference

Nov 13, 2023, 7:00 AM EST - 2 years ago

Leap Therapeutics Reports Third Quarter 2023 Financial Results

Sep 5, 2023, 7:00 AM EDT - 2 years ago

Leap Therapeutics to Participate at Upcoming Investor Conferences

Aug 14, 2023, 7:00 AM EDT - 2 years ago

Leap Therapeutics Reports Second Quarter 2023 Financial Results

Jul 12, 2023, 7:00 AM EDT - 2 years ago

Leap Therapeutics Announces Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer Patients

Jun 20, 2023, 12:30 PM EDT - 2 years ago

Leap Therapeutics Announces Reverse Stock Split

May 25, 2023, 5:10 PM EDT - 3 years ago

Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting

May 15, 2023, 7:00 AM EDT - 3 years ago

Leap Therapeutics Reports First Quarter 2023 Financial Results

Apr 12, 2023, 7:00 AM EDT - 3 years ago

Leap Therapeutics Announces Completion of Enrollment in Part A of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

Mar 24, 2023, 7:00 AM EDT - 3 years ago

Leap Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

Mar 16, 2023, 4:05 PM EDT - 3 years ago

Leap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01

atechniqueisause Mar. 14 at 12:34 AM

$CYPH So, earnings report on Tuesday? We expecting something?

1 · Reply

DubLad76 Mar. 13 at 8:38 PM

$CYPH how does this price make any sense?

0 · Reply

atechniqueisause Mar. 13 at 1:44 PM

$CYPH Let's go bros!

0 · Reply

BiodegradableBurger Mar. 13 at 8:46 AM

$CYPH Looking forward to the next pump.

0 · Reply

wutzwrong Mar. 13 at 3:58 AM

$CYPH earnings 3/17

0 · Reply

DubLad76 Mar. 12 at 5:08 PM

$CYPH keep on buying till I average down to 0.50 Then, well, wait for the big bounce.

0 · Reply

StockDreamin Mar. 12 at 2:12 PM

$CYPH antique sauce is on a roll! Yeah buddy!

1 · Reply

atechniqueisause Mar. 12 at 1:28 PM

$CYPH Cypherhunks?, Cypherchumps?, Cypherflunks?

0 · Reply

DubLad76 Mar. 11 at 9:06 PM

$CYPH

1 · Reply

Insideroutcalls Mar. 11 at 3:53 PM

$CYPH

0 · Reply

StockDreamin Mar. 11 at 3:25 PM

$CYPH cypherstrikeout

0 · Reply

Walter100 Mar. 11 at 2:53 PM

$CYPH https://www.coindesk.com/business/2026/03/10/mining-giant-foundry-to-introduce-institutional-zcash-mining-pool

0 · Reply

atechniqueisause Mar. 11 at 1:47 AM

$CYPH Cypherhunk?

0 · Reply

atechniqueisause Mar. 10 at 3:17 PM

$CYPH Cypherhunk?

0 · Reply

abc12379593827 Mar. 10 at 2:45 PM

$BTC.X $MSTR $CYPH and nobody knows why

0 · Reply

RoarinKitty Mar. 10 at 12:24 PM

$CYPH Atechn, what you don't understand is that on 3/4/26, CYPH got a delisting notice, which now gives us 180 days to get the stock price above $1 for 10 consecutive days. If the company's Zcash holdings are $90M, and the entire company has a market cap of only $29M, then why doesn't the company buy back some of its stock and help prop up the share price, and get us above $1???????????

1 · Reply

atechniqueisause Mar. 10 at 12:17 PM

$CYPH Brothers, I care less about the exact worth and more about our stock price going up. I really don't care, just make us some money!

0 · Reply

RoarinKitty Mar. 10 at 11:32 AM

MODRICA3, THIS IS THEIR HOLDINGS, ACCORDING TO THEIR FILINGS: "$CYPH If this is true: "Cypherpunk’s current total ZEC holdings stand at 294,743.10, at an average price of $335.89." MULTIPLY THOSE TWO NUMBERS AND TELL ME HOW YOU GET $60M AND NOT $90M???????????? IT'S $90M.

0 · Reply

RoarinKitty Mar. 10 at 11:28 AM

$CYPH MODRICA3 DOESN'T KNOW HOW TO MULTIPLY. THEIR ZCASH HOLDINGS ARE WORTH $90 MILLION.

0 · Reply

DubLad76 Mar. 10 at 11:01 AM

$CYPH Big bulls, put it all on the line. Come on the $CYPH and $ZEC.X Bring on the Clarity Act! Then, BOOM 💥

0 · Reply

StockDreamin Mar. 9 at 11:39 PM

$CYPH cypherpsych

1 · Reply

modrica3 Mar. 9 at 10:50 PM

$CYPH well their zcash holding currently at zec 216 is around $ 64 millions not $100 millions current cap is around 30 mill maybe because peeps are s\expecting zec to go down , that might be one reason

1 · Reply

Market Cap	24.04M
Revenue (ttm)	0.00
Net Income (ttm)	-67.56M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,777,500
Avg Vol	2,785,790
Day's Range	N/A - N/A
Shares Out	41.44M
Stochastic %K	33%
Beta	-0.16
Analysts	Strong Buy
Price Target	N/A